Watson Pharmaceuticals - Q2CY12 Result Excerpts:: Edelweiss Research PDF link

Watson Pharmaceuticals (WPI) started the year with EUR4.25bn acquisition of Actavis thereby strengthening the business in South East Asia, Australia and Central and Eastern Europe. The company expects to consolidate the acquired business by Q4CY12. Its Q2CY12 numbers show a 25% growth in sales and 42% in earnings. Watson management is positive on the long term growth outlook of business and sees strong levers for growth over 2013-16 from Actavis, generic opportunities in the US including Concerta, Lidoderm, US branded franchise and biosimilars. It expects to launch the first biosimilar FSH in certain markets out of Amgen collaboration by 2015-16.